| USA TODAY
Distilleries across the U.S. received a surprise bill from the Food and Drug Administration after using their facilities to make hand sanitizer amid the COVID-19 pandemic.
As COVID-19 cases began surging in March, distilleries started making hand sanitizer by switching their alcohol production to antiseptic, undrinkable alcohol and giving away bottles to members of their communities.
The efforts rose after the country faced a shortage in hand sanitizer as shoppers panic bought hand soap, cleaning wipes and other sanitation products.
The FDA issued a temporary non-prescription drug policy that same month, stating distilleries that produced sanitizer were classified as “over-the-counter drug monograph facilities.” These types of facilities must pay user fees under regulations set under the CARES Act.
The fees impacting distillers are a $14,060 Monograph Drug Facility Fee and $9,373 Contract Manufacturing Organization Facility Fee due on Feb. 11.
Who’s left out?: Here’s who doesn’t get the $600 stimulus check
“This incredibly frustrating news comes as a complete shock to the more than 800 distilleries across the country that came to the aid of their local communities and first responders,” said Distilled Spirits Council President and CEO Chris Swonger. “This unexpected fee serves to punish already struggling distilleries who jumped in at a time of need to do the right thing.”
Distilleries planing to avoid paying fees in 2022 should update their status as an over-the-counter monograph drug production facility with the FDA and cease producing and selling the product by Dec. 31, 2020.
“What’s unfortunate about this situation is that this was provided to us on such short notice,” said CEO of Saint Augustine Distillery, Philip McDaniel. “Everybody wishes we would have had more time to react and have more time to plan.”
Follow Coral Murphy on Twitter @CoralMerfi